Avecho Biotechnology (ASX:AVE) and Sandoz have signed an exclusive ten-year development and licensing agreement for the commercial rights to the Australian company's phase 3 cannabidiol capsule for insomnia in Australia.
Sandoz backs Australian medicinal cannabis company in ten-year agreement
March 3, 2025 BioPharmaAustralian Biotech
Latest Video
New Stories
-
Eisai and Biogen working on next steps after TGA confirms non-approval of Alzheimer’s therapy
March 4, 2025 - - Latest News -
CSL Seqirus secures Australia-NZ rights to commercialise cholesterol-lowering therapy
March 4, 2025 - - Latest News -
Is personalised gene therapy ready for prime time?
March 4, 2025 - - Latest News -
Astellas welcomes TGA approval of cancer combination as first-line treatment
March 4, 2025 - - Latest News -
Sandoz backs Australian medicinal cannabis company in ten-year agreement
March 3, 2025 - - BioPharma -
Australian startup launches the world's first commercial biological computer
March 3, 2025 - - Australian Biotech -
TGA approves first biological therapy for serious respiratory condition
March 3, 2025 - - Latest News